Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Open-label, Three-cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)

NCT01201915 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01201915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01201915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Open-label, Three-cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
May 31, 2013
Enrollment
74 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell carcinoma